Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Inhibrx | 2025 | Post Ipo Debt | $150.0M | La Jolla |
| Verdiva Bio | 2025 | Series A | $411.0M | London |
| Interius BioTherapeutics | 2025 | Undisclosed | $21.5M | Philadelphia |
| TScan Therapeutics | 2024 | Post Ipo Equity | $30.0M | Waltham |
| New Amsterdam Pharma | 2024 | Post Ipo Equity | $452.6M | Naarden |
| MARS | 2024 | Seed | $2.8M | Besiktas |
| Janux Therapeutics | 2024 | Post Ipo Equity | $350.0M | La Jolla |
| Bia Energy | 2024 | Convertible Note | $8.5M | Bogotá |
| ADCendo | 2024 | Series B | $135.0M | Copenhagen |
| Cortica | 2024 | Series Unknown | $80.0M | San Diego |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 251 | Inhibrx | Post Ipo Debt | $150.0M | La Jolla, United States |
| 252 | Verdiva Bio | Series A | $411.0M | London, United Kingdom |
| 253 | Interius BioTherapeutics | Undisclosed | $21.5M | Philadelphia, United States |
| 254 | TScan Therapeutics | Post Ipo Equity | $30.0M | Waltham, United States |
| 255 | New Amsterdam Pharma | Post Ipo Equity | $452.6M | Naarden, The Netherlands |
| 256 | MARS | Seed | $2.8M | Besiktas, Turkey |
| 257 | Janux Therapeutics | Post Ipo Equity | $350.0M | La Jolla, United States |
| 258 | Bia Energy | Convertible Note | $8.5M | Bogotá, Colombia |
| 259 | ADCendo | Series B | $135.0M | Copenhagen, Denmark |
| 260 | Cortica | Series Unknown | $80.0M | San Diego, United States |
Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.
Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.
Interius BioTherapeutics is a biotechnology company that delivers genetic medicines for patients.
TScan Therapeutics is a biopharmaceutical company focused on the development of immunotherapy treatments for cancer.
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
MARS provides digital financial services with unique card options and rewards programs.
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
Bia Energy is transforming LatAm’s power sector with smart meters and a digital platform for real-time control, savings, and sustainability.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.
Cortica provides neurological therapies for children with autism and other developmental differences.
We provide neurodegenerative disease patients with expert MDs and 24/7 wrap around care, no matter where you live in the US
Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.
ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.
Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients.
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Alpha-9 Oncology is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
Ervaxx is illuminating the immune interface to develop new cancer therapies.
Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
Navigator Medicines operate as a biotech company.
Elektrofi develops hyper concentration microparticle technology for subcutaneous biologic medicine delivery.
Halda Therapeutics is a research-stage drug discovery company.
Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.
MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
Outpace Bio develops innovative cell therapies to enhance cancer treatment efficacy.
RA Capital Management has invested in 369 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Life Science, Pharmaceutical. The firm invests across 22 different industry categories.
Among tracked funding rounds, New Amsterdam Pharma received $452.6M in a Post Ipo Equity round. RA Capital Management's total known invested capital is $19.0B.
RA Capital Management's average investment size is $91.5M across its portfolio of 369 companies.
Recent RA Capital Management portfolio additions include Inhibrx, Verdiva Bio, Interius BioTherapeutics, TScan Therapeutics, New Amsterdam Pharma. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors